Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Clinical depression puts pregnant women at increased risk of delivering prematurely and of giving birth to below-normal weight infants, according to a report published Oct. 4 in the Archives of General Psychiatry.

5 Oct 2010

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Depression treatment guidelines updated

There has been an update in the treatment of clinical depression. This includes suggestions on the use of medication, talk therapy, exercise, and alternative treatments and puts more emphasis on tailor made treatments for patients.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®.

1 Oct 2010

Increase in sales of new antidepressants not linked to decline in suicide rate

Many researchers have studied the relationship between the increase in sales of new antidepressants in recent decades and a simultaneous decline in the suicide rate. In a study based on figures from the Nordic countries, researchers at the Norwegian Institute of Public Health found no evidence that increased sales of the new medicines could be linked to a lower suicide rate. The researchers also did not find any relationship between reduced sales of the older and more toxic antidepressants and a reduction in suicide rates.

30 Sep 2010

Researchers discover new drug to control acute and chronic pain

American and Italian researchers have found that a novel drug allows anandamide a marijuana like chemical in the body to effectively control pain at the site of an injury.

21 Sep 2010

Researchers reveal Prozac reactions to increase serotonin level

The response time to antidepressants, such as Prozac, is around three weeks. The adaptation mechanisms of the neurons to antidepressants has, until now, remained enigmatic. In particular, the researchers have revealed, for the first time, a sequence of reactions caused by Prozac at the neuron level, which contributes to an increase in the amounts of serotonin, a chemical "messenger" essential to the brain, and deficient in depressive individuals.

17 Sep 2010

Complementary medicine to save millions: Report

According to a new report substituting pharmaceutical antidepressants with St John’s Wort could save the health system $50 million a year. This research was conducted by Access Economics for the National Institute of Complementary Medicine (NICM) at the University of Western Sydney. It showed that cost effectiveness of complementary and alternative therapies have the potential to cut costs without compromising patient outcomes.

13 Sep 2010

Laser acupuncture a plausible treatment for depression

Acupuncture produces significant changes in parts of the brain that regulate emotional states and is a biologically plausible treatment for depression and other neuropsychiatric disorders, Australian researchers have shown for the first time.

13 Sep 2010

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

A drug developed at the University of Kansas has the potential to stop a debilitating condition of diabetes that often leads to pain in the extremities and even amputations, KU researchers have found.

13 Sep 2010

Study reveals high rate of parental depression in first year after child's birth

More than one-third of mothers and about one-fifth of fathers in the United Kingdom appear to experience an episode of depression between their child's birth and 12th year of age, with the highest rates in the first year after birth, according to a report posted online today that will appear in the November print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

Depression is actually defined by specific clinical symptoms such as sadness, difficulty to experience pleasure, sleep problems etc., present for at least two weeks, with impairment of psychosocial functioning. These symptoms guide the physician to make a diagnosis and to select antidepressant treatment such as drugs or psychotherapy.

31 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Study finds ketamine restores connection in chronic stress affected brain cells

Yale researchers have discovered how a novel anti-depressant can take effect in hours, rather than the weeks or months usually required for most drugs currently on the market.

20 Aug 2010

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

20 Aug 2010

Antidepressant News and Research

Further Reading

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

Depression treatment guidelines updated

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Increase in sales of new antidepressants not linked to decline in suicide rate

Researchers discover new drug to control acute and chronic pain

Researchers reveal Prozac reactions to increase serotonin level

Complementary medicine to save millions: Report

Laser acupuncture a plausible treatment for depression

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

Study reveals high rate of parental depression in first year after child's birth

SAMe dietary supplement effective for major depressive disorders: Study

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Study finds ketamine restores connection in chronic stress affected brain cells

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News